Inotiv
CLOSE ×

 

Inotiv-NAFLD-NASH-mini-paper

As obesity and related metabolic disorders continue to rise, nonalcoholic steatohepatitis (NASH) has become the second most common cause of liver transplantation, yet no NASH-specific therapy has been approved. Animal models continue to play a key role in helping develop treatment options and revealing new information about its pathogenesis.

Download our insightful mini paper to understand how to:

  • Induce obesity, metabolic syndrome, and mild NASH
  • Induce hepatic features of severe NASH - without inducing metabolic symptoms such as obesity and insulin resistance
  • Understand the key considerations when choosing a rodent diet

Complete the form to download the "Diets to induce nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)" mini-paper today.

 

Download today!